{"id":452467,"date":"2021-03-08T08:03:22","date_gmt":"2021-03-08T13:03:22","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=452467"},"modified":"2021-03-08T08:03:22","modified_gmt":"2021-03-08T13:03:22","slug":"cortexyme-announces-partnership-with-parkinson-study-group-and-upcoming-alzheimers-disease-data-presentation","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cortexyme-announces-partnership-with-parkinson-study-group-and-upcoming-alzheimers-disease-data-presentation\/","title":{"rendered":"Cortexyme Announces Partnership with Parkinson Study Group and Upcoming Alzheimer\u2019s Disease Data Presentation"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position:inside; }\n.bwlistdisc { list-style-type: disc; }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\" style=\"font-weight:normal\"><b>Cortexyme Announces Partnership with Parkinson Study Group and Upcoming Alzheimer\u2019s Disease Data Presentation<\/b><\/p>\n<p class=\"bwalignc\"><i>&#8212; Partnership with Parkinson Study Group Advisory Panel to collaborate on Parkinson\u2019s Disease Program &#8212;<\/i><\/p>\n<p class=\"bwalignc\"><i>&#8212; Presentation at AD\/PD\u2122 2021 Underscores Relevance of Cortexyme\u2019s Approach &#8212;<\/i><\/p>\n<p>SOUTH SAN FRANCISCO, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nCortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer\u2019s and other degenerative diseases, announced that it has partnered with the Parkinson Study Group (PSG) to form an Advisory Board to leverage the group\u2019s expertise and further develop the company\u2019s Parkinson\u2019s disease (PD) program. In addition, Cortexyme will present new data further demonstrating the role of <i>Porphyromonas gingivalis<\/i><i>(P. gingivalis)<\/i> in the development of Alzheimer\u2019s disease at AD\/PD\u2122 2021, the 15<sup>th<\/sup> International Conference on Alzheimer\u2019s &amp; Parkinson\u2019s Diseases, which is being held virtually March 9-14, 2021.\n<\/p>\n<p>\nHubert Fernandez, M.D., Co-Chair of the Parkinson Study Group Executive Committee and Chair of the PSG Credentialing Committee, and a member of the newly created Advisory Board, stated: \u201cI look forward to working with my colleagues on the Advisory Board. We are collectively eager to further understand the mechanism of gingipain inhibition and its potential to improve the lives of patients suffering from Parkinson\u2019s disease. There is a tremendous unmet medical need for PD, and the potential link between <i>P. gingivalis<\/i> and PD demands further exploration.\u201d\n<\/p>\n<p>\nAlong with Fernandez, the new Cortexyme\/PSG Advisory Board is comprised of expert researchers across the PD field:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nPatrik Brundin, M.D., Ph.D., Honorary Guest to the PSG\n<\/li>\n<li>\nEric Macklin, Ph.D., PSG Executive Committee Member\n<\/li>\n<li>\nZoltan Mari, M.D., Co-Chair of the PSG Motor Features of PD Working Group\n<\/li>\n<li>\nAndrew Siderowf, M.D., PSG Executive Committee Member\n<\/li>\n<\/ul>\n<p>\n\u201cOur partnership with the PSG demonstrates the importance of Cortexyme\u2019s evidence to date and the potential to benefit patients suffering from Parkinson\u2019s disease,\u201d said Michael Detke, M.D., Ph.D., Cortexyme\u2019s Chief Medical Officer. \u201cWe are pleased to partner with the PSG and look forward to advancing our work in Parkinson\u2019s disease as we make progress towards improving patient outcomes.\u201d\n<\/p>\n<p>\nMounting evidence supports the role of <i>P. gingivalis<\/i> in Parkinson\u2019s disease, including research supporting the epidemiological link between periodontal disease and Parkinson\u2019s disease and rodent studies demonstrating that oral <i>P. gingivalis <\/i>infection<i \/>causes alpha-synuclein production and degeneration of dopamine-producing neurons in the substantia nigra of the brain. For further details, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.cortexyme.com%2Fscience&amp;esheet=52391924&amp;newsitemid=20210308005240&amp;lan=en-US&amp;anchor=www.cortexyme.com%2Fscience&amp;index=1&amp;md5=7c25d09dc312c530e97d94126022f715\">www.cortexyme.com\/science<\/a>.\n<\/p>\n<p><b>AD\/PD 2021 Presentation Furthers Link Between <i>P. gingivalis<\/i> and Neurodegeneration<\/b><\/p>\n<p>\nCortexyme will also present research (poster 131\/abstract 1544) at AD\/PD 2021 further reinforcing Cortexyme\u2019s foundational research on <i>P. gingivalis\u2019<\/i> role in AD and new techniques to detect the presence of <i>P. gingivalis<\/i> in the human brain.\n<\/p>\n<p>\nIn the poster, scientists at the University of Auckland and Cortexyme report new techniques to determine the ultrastructural localization of the arginine-gingipain (Rgp) virulence factor secreted by <i>P. gingivalis<\/i> in the human AD brain using electron microscopy. The researchers will report on the intracellular organelles in AD brain cells that Rgp co-localizes with, providing insight for the first time on why some sub-cellular organelles in AD neurons and astrocytes are damaged.\n<\/p>\n<p>\n\u201cThis research adds to the growing body of evidence that shows the presence of gingipains in the human AD brain and the validation of new electron microscopy techniques that can be leveraged for future research into sub-cellular localization of gingipains within neurons and astrocytes,\u201d said Stephen Dominy, M.D., Cortexyme\u2019s Co-Founder and Chief Scientific Officer.\n<\/p>\n<p>\nView the abstract \u201cUltrastructural localization of <i>Porphyromonas gingivalis<\/i> RgpB virulence factor in the middle temporal gyrus (MTG) of the Alzheimer\u2019s disease human brain\u201d <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cortexyme.com%2Fscience%2F&amp;esheet=52391924&amp;newsitemid=20210308005240&amp;lan=en-US&amp;anchor=here&amp;index=2&amp;md5=07963b13b9c4f2e712fb01e4c7ee8068\">here<\/a><i \/>on Cortexyme\u2019s website following the conference.\n<\/p>\n<p><b>About Cortexyme<\/b><\/p>\n<p>\nCortexyme, Inc. (Nasdaq: CRTX) is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer\u2019s and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2\/3 clinical trial in patients with mild to moderate Alzheimer\u2019s disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models. To learn more about Cortexyme, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cortexyme.com%2F&amp;esheet=52391924&amp;newsitemid=20210308005240&amp;lan=en-US&amp;anchor=www.cortexyme.com&amp;index=3&amp;md5=ed0bc171c3216a64932494091881555e\">www.cortexyme.com<\/a> or follow @Cortexyme on Twitter.\n<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nStatements in this press release contain \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cexpect,\u201d \u201cbelieve,\u201d \u201cwill,\u201d \u201cmay,\u201d \u201cshould,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201coutlook,\u201d \u201cforecast\u201d or other similar words. Examples of forward-looking statements include, among others, statements we make regarding the partial clinical hold and ongoing correspondence with the FDA, and its related impact on the timing and success of our clinical trials, including with respect to atuzaginstat, the double-blind, placebo-controlled randomized phase of the GAIN Trial and open-label extension phase; the timing of announcements and updates relating to our clinical trials and related data; the potential therapeutic benefits, safety and efficacy of our product candidate or library of compounds; statements about our ability to obtain, and the timing relating to, and regulatory submissions and approvals with respect to our drug product candidate. Forward-looking statements are based on Cortexyme\u2019s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled \u201cRisk Factors\u201d in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 1, 2021, our Quarterly Report on Form 10-Q filed with the SEC on November 12, 2020, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Cortexyme undertakes no duty to update such information except as required under applicable law.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210308005240r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210308005240\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210308005240\/en\/<\/a><\/span><\/p>\n<p><b>Corporate Contact:<br \/>\n<\/b><br \/>Chris Lowe<br \/>\n<br \/>Chief Operating Officer<br \/>\n<br \/>Cortexyme, Inc.<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:clowe@cortexyme.com\">clowe@cortexyme.com<\/a><\/p>\n<p><b>Investor Contact:<br \/>\n<\/b><br \/>Corey Davis, Ph.D.<br \/>\n<br \/>LifeSci Advisors<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:cdavis@lifesciadvisors.com\">cdavis@lifesciadvisors.com<br \/>\n<\/a><br \/>(212) 915-2577\n<\/p>\n<p><b>Media Contact:<br \/>\n<\/b><br \/>Hal Mackins<br \/>\n<br \/>For Cortexyme, Inc.<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:hal@torchcomllc.com\">hal@torchcomllc.com<br \/>\n<\/a><br \/>(415) 994-0040\n<\/p>\n<p><b>KEYWORDS:<\/b> United States North America California<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Mental Health Health Infectious Diseases Dental Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210308005240\/en\/632816\/3\/Cortexyme_logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Cortexyme Announces Partnership with Parkinson Study Group and Upcoming Alzheimer\u2019s Disease Data Presentation &#8212; Partnership with Parkinson Study Group Advisory Panel to collaborate on Parkinson\u2019s Disease Program &#8212; &#8212; Presentation at AD\/PD\u2122 2021 Underscores Relevance of Cortexyme\u2019s Approach &#8212; SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211; Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer\u2019s and other degenerative diseases, announced that it has partnered with the Parkinson Study Group (PSG) to form an Advisory Board to leverage the group\u2019s expertise and further develop the company\u2019s Parkinson\u2019s disease (PD) program. In addition, Cortexyme will present new data further demonstrating the role of Porphyromonas gingivalis(P. gingivalis) in the development of Alzheimer\u2019s disease at AD\/PD\u2122 2021, the 15th International Conference on Alzheimer\u2019s &amp; &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cortexyme-announces-partnership-with-parkinson-study-group-and-upcoming-alzheimers-disease-data-presentation\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cortexyme Announces Partnership with Parkinson Study Group and Upcoming Alzheimer\u2019s Disease Data Presentation&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-452467","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cortexyme Announces Partnership with Parkinson Study Group and Upcoming Alzheimer\u2019s Disease Data Presentation - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cortexyme-announces-partnership-with-parkinson-study-group-and-upcoming-alzheimers-disease-data-presentation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cortexyme Announces Partnership with Parkinson Study Group and Upcoming Alzheimer\u2019s Disease Data Presentation - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Cortexyme Announces Partnership with Parkinson Study Group and Upcoming Alzheimer\u2019s Disease Data Presentation &#8212; Partnership with Parkinson Study Group Advisory Panel to collaborate on Parkinson\u2019s Disease Program &#8212; &#8212; Presentation at AD\/PD\u2122 2021 Underscores Relevance of Cortexyme\u2019s Approach &#8212; SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211; Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer\u2019s and other degenerative diseases, announced that it has partnered with the Parkinson Study Group (PSG) to form an Advisory Board to leverage the group\u2019s expertise and further develop the company\u2019s Parkinson\u2019s disease (PD) program. In addition, Cortexyme will present new data further demonstrating the role of Porphyromonas gingivalis(P. gingivalis) in the development of Alzheimer\u2019s disease at AD\/PD\u2122 2021, the 15th International Conference on Alzheimer\u2019s &amp; &hellip; Continue reading &quot;Cortexyme Announces Partnership with Parkinson Study Group and Upcoming Alzheimer\u2019s Disease Data Presentation&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cortexyme-announces-partnership-with-parkinson-study-group-and-upcoming-alzheimers-disease-data-presentation\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-08T13:03:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210308005240r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cortexyme-announces-partnership-with-parkinson-study-group-and-upcoming-alzheimers-disease-data-presentation\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cortexyme-announces-partnership-with-parkinson-study-group-and-upcoming-alzheimers-disease-data-presentation\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cortexyme Announces Partnership with Parkinson Study Group and Upcoming Alzheimer\u2019s Disease Data Presentation\",\"datePublished\":\"2021-03-08T13:03:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cortexyme-announces-partnership-with-parkinson-study-group-and-upcoming-alzheimers-disease-data-presentation\\\/\"},\"wordCount\":1097,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cortexyme-announces-partnership-with-parkinson-study-group-and-upcoming-alzheimers-disease-data-presentation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210308005240r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cortexyme-announces-partnership-with-parkinson-study-group-and-upcoming-alzheimers-disease-data-presentation\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cortexyme-announces-partnership-with-parkinson-study-group-and-upcoming-alzheimers-disease-data-presentation\\\/\",\"name\":\"Cortexyme Announces Partnership with Parkinson Study Group and Upcoming Alzheimer\u2019s Disease Data Presentation - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cortexyme-announces-partnership-with-parkinson-study-group-and-upcoming-alzheimers-disease-data-presentation\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cortexyme-announces-partnership-with-parkinson-study-group-and-upcoming-alzheimers-disease-data-presentation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210308005240r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-03-08T13:03:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cortexyme-announces-partnership-with-parkinson-study-group-and-upcoming-alzheimers-disease-data-presentation\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cortexyme-announces-partnership-with-parkinson-study-group-and-upcoming-alzheimers-disease-data-presentation\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cortexyme-announces-partnership-with-parkinson-study-group-and-upcoming-alzheimers-disease-data-presentation\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210308005240r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210308005240r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cortexyme-announces-partnership-with-parkinson-study-group-and-upcoming-alzheimers-disease-data-presentation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cortexyme Announces Partnership with Parkinson Study Group and Upcoming Alzheimer\u2019s Disease Data Presentation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cortexyme Announces Partnership with Parkinson Study Group and Upcoming Alzheimer\u2019s Disease Data Presentation - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cortexyme-announces-partnership-with-parkinson-study-group-and-upcoming-alzheimers-disease-data-presentation\/","og_locale":"en_US","og_type":"article","og_title":"Cortexyme Announces Partnership with Parkinson Study Group and Upcoming Alzheimer\u2019s Disease Data Presentation - Market Newsdesk","og_description":"Cortexyme Announces Partnership with Parkinson Study Group and Upcoming Alzheimer\u2019s Disease Data Presentation &#8212; Partnership with Parkinson Study Group Advisory Panel to collaborate on Parkinson\u2019s Disease Program &#8212; &#8212; Presentation at AD\/PD\u2122 2021 Underscores Relevance of Cortexyme\u2019s Approach &#8212; SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211; Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer\u2019s and other degenerative diseases, announced that it has partnered with the Parkinson Study Group (PSG) to form an Advisory Board to leverage the group\u2019s expertise and further develop the company\u2019s Parkinson\u2019s disease (PD) program. In addition, Cortexyme will present new data further demonstrating the role of Porphyromonas gingivalis(P. gingivalis) in the development of Alzheimer\u2019s disease at AD\/PD\u2122 2021, the 15th International Conference on Alzheimer\u2019s &amp; &hellip; Continue reading \"Cortexyme Announces Partnership with Parkinson Study Group and Upcoming Alzheimer\u2019s Disease Data Presentation\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cortexyme-announces-partnership-with-parkinson-study-group-and-upcoming-alzheimers-disease-data-presentation\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-08T13:03:22+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210308005240r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cortexyme-announces-partnership-with-parkinson-study-group-and-upcoming-alzheimers-disease-data-presentation\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cortexyme-announces-partnership-with-parkinson-study-group-and-upcoming-alzheimers-disease-data-presentation\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cortexyme Announces Partnership with Parkinson Study Group and Upcoming Alzheimer\u2019s Disease Data Presentation","datePublished":"2021-03-08T13:03:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cortexyme-announces-partnership-with-parkinson-study-group-and-upcoming-alzheimers-disease-data-presentation\/"},"wordCount":1097,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cortexyme-announces-partnership-with-parkinson-study-group-and-upcoming-alzheimers-disease-data-presentation\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210308005240r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cortexyme-announces-partnership-with-parkinson-study-group-and-upcoming-alzheimers-disease-data-presentation\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cortexyme-announces-partnership-with-parkinson-study-group-and-upcoming-alzheimers-disease-data-presentation\/","name":"Cortexyme Announces Partnership with Parkinson Study Group and Upcoming Alzheimer\u2019s Disease Data Presentation - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cortexyme-announces-partnership-with-parkinson-study-group-and-upcoming-alzheimers-disease-data-presentation\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cortexyme-announces-partnership-with-parkinson-study-group-and-upcoming-alzheimers-disease-data-presentation\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210308005240r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-03-08T13:03:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cortexyme-announces-partnership-with-parkinson-study-group-and-upcoming-alzheimers-disease-data-presentation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cortexyme-announces-partnership-with-parkinson-study-group-and-upcoming-alzheimers-disease-data-presentation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cortexyme-announces-partnership-with-parkinson-study-group-and-upcoming-alzheimers-disease-data-presentation\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210308005240r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210308005240r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cortexyme-announces-partnership-with-parkinson-study-group-and-upcoming-alzheimers-disease-data-presentation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cortexyme Announces Partnership with Parkinson Study Group and Upcoming Alzheimer\u2019s Disease Data Presentation"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/452467","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=452467"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/452467\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=452467"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=452467"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=452467"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}